Discovery of c-Kit as a New Therapeutic Target in LPS-Induced Acute Lung Injury through Novel Phenylamide Derivative D9
- J Med Chem. 2025 Apr 10;68(7):7499-7517. doi: 10.1021/acs.jmedchem.4c03229.
- 1. Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- 2. Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
- 3. College of Pharmacy, Chonnam National University, Gwangju 61186, South Korea.
- 4. Department of Pharmacy, Wenzhou Nursing School, Wenzhou, Zhejiang 325000, China.
- 5. Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy, Yanji, Jilin 133002, China.
- 6. School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China.
Discovering effective anti-inflammatory drugs and targets is a critical research priority. Herein, 28 novel phenylamide derivatives were designed and synthesized. Compound D9 showed favorable anti-inflammatory activities in acute lung injury (ALI) and sepsis mouse models. The target of D9 was predicted and studied, and c-Kit was identified by surface plasmon resonance (SPR) and cellular thermal shift assay (CETSA), which demonstrated high selectivity in kinase activity profiling. It was further verified that c-Kit participated in the LPS-induced inflammatory response in J774A.1, RAW264.7, MPMs, and lung tissue. Additionally, c-Kit is proved to be essential for LPS-induced activation of the NF-κB pathway. Finally, c-Kit was confirmed as a therapeutic target in the LPS-induced ALI with c-Kit gene knockdown and was further verified as the target of D9. Notably, there has been no report of c-Kit's influence on the LPS-induced inflammatory response. Therefore, c-Kit was identified as a new therapeutic target for the LPS-induced ALI.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: c-KitResearch Areas: Inflammation/Immunology